2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal Of Medicine 2021, 385: 1280-1291. PMID: 34587385, DOI: 10.1056/nejmoa2033617.Peer-Reviewed Original ResearchConceptsActive ulcerative colitisMaintenance therapyUlcerative colitisClinical remissionEnd pointClinical responseCohort 2Cohort 1Selective sphingosine-1-phosphate receptor modulatorSphingosine-1-phosphate receptor modulatorsElevated liver aminotransferase levelsKey secondary end pointLiver aminotransferase levelsPlacebo-controlled trialPrimary end pointSecondary end pointsPercentage of patientsDouble-blind mannerInflammatory bowel diseaseSame daily doseIncidence of infectionHistologic end pointsMayo scoreUnderwent randomizationAminotransferase levels
2016
Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis
Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2016, 111: 1692. PMID: 27725645, DOI: 10.1038/ajg.2016.418.Peer-Reviewed Original ResearchConceptsRelapse/exacerbationHistological remissionEndoscopic remissionClinical remissionHistological activityClinical outcomesUlcerative colitisHistological statusClinical relapseHistological featuresLamina propriaChronic inflammatory cell infiltrateAdditional prognostic utilityHistological disease activityProportion of patientsInflammatory bowel diseaseInflammatory cell infiltrateLack of blindingImproved clinical outcomesDifferent histological featuresSpecific histological featuresRandom-effects modelFixed-effects modelDisease activityUC patients